Baseline demographics
| Characteristic . | Fixed-dose enoxaparin (n = 23) . | Weight-adjusted enoxaparin (n = 24) . |
|---|---|---|
| Female, n (%) | 15 (65) | 15 (62) |
| Age, median (range), y | 60 (28-83) | 61 (43-76) |
| Weight, median (range), kg | 82 (53-109) | 76 (61-124) |
| BMI, median (range), kg/m2 | 30 (20-40) | 30 (20-44) |
| Khorana site of cancer category, n (%) | ||
| Very high risk | 3 (13) | 3 (13) |
| High risk | 11 (48) | 12 (50) |
| Standard risk | 9 (39) | 9 (38) |
| Padua score, n (%) | ||
| 4 | 9 (39) | 14 (58) |
| 5-7 | 12 (52) | 8 (33) |
| >8 | 2 (8) | 2 (8) |
| Tumor type, n (%) | ||
| Lymphoma | 9 (39) | 7 (29) |
| Gastrointestinal | 4 (17) | 4 (17) |
| Pancreatic | 3 (13) | 3 (12) |
| Sarcoma | 3 (13) | 3 (12) |
| Breast | 2 (9) | 1 (4) |
| Glioblastoma | 1 (4) | 0 (0) |
| Myeloma | 0 (0) | 2 (8) |
| Other | 1 (4) | 4 (17) |
| Characteristic . | Fixed-dose enoxaparin (n = 23) . | Weight-adjusted enoxaparin (n = 24) . |
|---|---|---|
| Female, n (%) | 15 (65) | 15 (62) |
| Age, median (range), y | 60 (28-83) | 61 (43-76) |
| Weight, median (range), kg | 82 (53-109) | 76 (61-124) |
| BMI, median (range), kg/m2 | 30 (20-40) | 30 (20-44) |
| Khorana site of cancer category, n (%) | ||
| Very high risk | 3 (13) | 3 (13) |
| High risk | 11 (48) | 12 (50) |
| Standard risk | 9 (39) | 9 (38) |
| Padua score, n (%) | ||
| 4 | 9 (39) | 14 (58) |
| 5-7 | 12 (52) | 8 (33) |
| >8 | 2 (8) | 2 (8) |
| Tumor type, n (%) | ||
| Lymphoma | 9 (39) | 7 (29) |
| Gastrointestinal | 4 (17) | 4 (17) |
| Pancreatic | 3 (13) | 3 (12) |
| Sarcoma | 3 (13) | 3 (12) |
| Breast | 2 (9) | 1 (4) |
| Glioblastoma | 1 (4) | 0 (0) |
| Myeloma | 0 (0) | 2 (8) |
| Other | 1 (4) | 4 (17) |